New Daiichi Structure Strengthens Oncology Focus
US-Based Global Unit Formed
Executive Summary
Japanese firm creates new US-based global organization that reaffirms strategic focus on oncology as main pillar of mid-term growth.
You may also be interested in...
AZ Bets Big On ADCs As It Inks Second, $6bn Deal With Daiichi
Following their original March 2019 tie-up for an oncology antibody-drug conjugate, Daiichi Sankyo and AstraZeneca have entered into a new global deal worth up to $6bn for a second novel asset from the Japanese firm, with potential in breast, lung and other cancers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Biomarin’s next chapter; Amgen’s obesity plans; Daiichi’s new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the rise of Novo Nordisk; senior level changes at Novartis; Moderna’s progress against BA.2.86; major new CNS drugs coming; and Boehringer Ingelheim’s head of innovation on R&D priorities.